# Inogen Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Inogen Inc). ## Overview Inogen Inc designs, markets, and sells portable and stationary oxygen concentrators and related respiratory products for people needing long-term oxygen therapy. The company sells through a mix of U.S. business-to-business channels, direct-to-consumer channels, and international distributors, with a growing emphasis on expanding its respiratory product portfolio and overseas reach. ## Products & services • Portable oxygen concentrators (POCs) • Stationary oxygen concentrators • Oxygen therapy accessories and replacement parts • Rental of oxygen concentrator systems in the U.S. • Respiratory products distributed through partners • Service contracts and freight-related revenue - **Portable oxygen concentrators** (55%) — Battery-powered and portable oxygen therapy devices sold to patients and channel partners. - **Stationary oxygen concentrators** (10%) — Home-use oxygen concentrators, including the Voxi 5 introduced through the Yuwell collaboration. - **Oxygen rentals** (15%) — U.S. rental revenue from concentrator deployments to patients on service. - **Accessories and replacement parts** (10%) — Consumables, replacement components, and related support items for installed devices. - **Partner-distributed respiratory products** (10%) — Third-party respiratory products distributed in the U.S. and selected international markets. - Portable oxygen concentrators (POCs) - Stationary oxygen concentrators - Oxygen therapy accessories and replacement parts - U.S. oxygen concentrator rentals - Partner-distributed respiratory products - Service contracts and freight revenue ## Customers Inogen sells primarily to home medical equipment providers, distributors, resellers, and other business partners that serve long-term oxygen therapy patients. It also sells direct to consumers in the U.S., where patients buy for cash or insurance-supported use, and it has some exposure to charitable organizations and large house accounts internationally. - **U.S. business-to-business partners** (primary) — HME providers, distributors, and resellers that buy concentrators to serve oxygen therapy patients and shift away from tank delivery models. - **Direct-to-consumer patients** (primary) — Patients purchasing directly in the U.S. through cash or insurance-related channels, often influenced by consumer advertising and prescriber outreach. - **International distributors and house accounts** (primary) — Distributors, resellers, gas companies, and home oxygen providers that buy for resale or local patient support across Europe and other markets. - **Private label and strategic collaborators** (secondary) — Channel partners and collaborators that broaden product access and help scale distribution into new markets and product lines. - **Charitable and institutional buyers** (secondary) — Smaller but relevant buyers that contribute to channel diversity and can support patient access programs. - U.S. HME providers that want non-delivery oxygen therapy solutions - Distributors and resellers that market and support the devices locally - Direct-to-consumer patients buying cash or insurance-supported products - International house accounts such as gas companies and oxygen providers - Private label and strategic channel partners that extend market reach ## Geography The U.S. remains the largest market, but international sales are a major part of the business and represented 39.8% of total revenue in 2025. Europe is the core overseas market, accounting for 85.0% of international sales in 2025, while the company also sells into several other regions and has begun using partners to expand in Asia-Pacific and Latin America. - **United States** (60.2%) — Derived from 2025 revenue by geographic region: U.S. sales 44.9% plus U.S. rentals 15.3%. - **International** (39.8%) — Reported as international sales in 2025. - U.S. sales were 44.9% of 2025 revenue - International sales were 39.8% of 2025 revenue - Europe accounted for 85.0% of international sales in 2025 - Netherlands site supports European sales and customer service - Czech Republic contract manufacturing supports European supply ## Strategy Inogen is focused on expanding its U.S. B2B channel, improving direct-to-consumer productivity, and increasing international adoption through distributors and regional support infrastructure. It is also broadening its product portfolio through the Yuwell collaboration, which adds respiratory products in the U.S. and selected overseas markets while supporting entry into China. - **Expand domestic B2B channel penetration** (short-term) — The U.S. market still has low POC penetration, so more HME and reseller adoption can drive volume growth. - **Increase international adoption** (medium-term) — Europe offers reimbursement-supported demand and the company already has a meaningful overseas base. - **Improve direct-to-consumer execution** (short-term) — Better lead generation and sales productivity can offset pressure in the consumer channel. - **Broaden the respiratory product portfolio** (medium-term) — New products can deepen channel relationships and reduce dependence on a narrow oxygen concentrator mix. - Expand U.S. HME provider and reseller network - Grow international B2B adoption, especially in Europe - Improve direct-to-consumer and prescriber sales productivity - Use the Yuwell collaboration to broaden product offerings - Support growth with European service and Czech manufacturing ## Risks The business is exposed to customer concentration, reimbursement complexity, and intense competition in respiratory care. It also depends on third-party manufacturers and distributors, so supply-chain disruption, regulatory issues, or weaker partner demand can quickly affect revenue and margins. - **Customer concentration** [high] — A small number of distributors, HME providers, and partners generate a large share of revenue, so lost volume can materially reduce sales. - **Reimbursement and payer dependence** [high] — A meaningful portion of demand depends on insurance and Medicare-related reimbursement, which can change utilization and economics. - **Competitive pressure** [medium] — The company operates in a crowded respiratory device market where rivals can win share through price, features, or channel relationships. - **Supplier and manufacturing dependence** [medium] — Reliance on contract manufacturers and limited suppliers can create quality, timing, and cost risks. - **Regulatory and compliance risk** [medium] — Medical devices are subject to FDA and international regulatory oversight, and additional clearances or enforcement actions could slow launches or sales. - **Cybersecurity and IT disruption** [medium] — Customer support, sales operations, and internal systems depend on networked IT infrastructure that can be attacked or fail. - Top customers account for a large share of revenue - Reimbursement rules can delay or reduce sales conversion - Competition may pressure pricing and channel share - Dependence on third-party manufacturers and suppliers - Cybersecurity and IT outages could disrupt operations ## Accounting Revenue recognition is important because Inogen sells through multiple channels, including product sales, rentals, service contracts, and freight-related revenue, each of which can be recognized differently. Goodwill and acquired intangible assets also matter because the company has made acquisitions and must test those assets for impairment, while rental asset deployments and customer collections affect timing of cash and reported results. - **Revenue recognition** — Point-in-time product sales versus rental/service recognition - **Goodwill and acquired intangible assets** — Potential non-cash impairment charges - **Rental asset accounting** — Affects operating expenses, assets, and cash flow presentation - **Allowance and credit risk** — Accounts receivable valuation and bad debt expense - Revenue recognition varies by product sales, rentals, and service contracts - Channel mix affects timing of revenue and gross margin - Rental assets create depreciation and deployment accounting complexity - Acquired intangibles and goodwill require impairment testing - Customer collections and prepayments affect cash flow timing --- *Last updated: 2026-04-28T20:17:35.457613+00:00*